ASX healthcare share rockets 9% on upgraded profit growth guidance

This healthcare player has confirmed high growth for FY25.

| More on:
a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

sdf

ASX healthcare share Fisher & Paykel Healthcare Corp Ltd (ASX: FPH) has rocketed out of the blocks on Friday after the company provided an update on its FY25 profit guidance.

Shares are racing 9% higher from the open and are fetching $32.00 apiece as investors react positively to the news.

Fisher & Paykel has been on a tear this year with the stock up 46.6% in that time, so today's price action continues this uptrend.

Let's see what the company posted.

Created with Highcharts 11.4.3Fisher & Paykel Healthcare PriceZoom1M3M6MYTD1Y5Y10YALL1 Aug 202323 Aug 2024Zoom ▾Sep '23Nov '23Jan '24Mar '24May '24Jul '24Sep '23Sep '23Jan '24Jan '24May '24May '24www.fool.com.au

ASX healthcare updates H1 guidance

After updating the market on its business performance so far in FY25, the ASX healthcare share revised its projections higher.

Revenue is now projected to fall between $940 million and $950 million for the first half of FY25, marking an 18% increase compared to H1 last year.

Fisher & Paykel management also expects net profits to jump by 44% in the first half to $160 million, which is at the upper end of estimates.

This comes after it grew sales by 10% in FY24, leading to a 6% growth in net profit for the year. As such, the company expects big growth this financial year.

Management said the growth was driven by several factors, including successful new product launches and a higher-than-expected hospital census in both the Northern and Southern Hemispheres.

The company has also made notable strides in improving its gross margins. CEO Lewis Gradon highlighted this progress:

The year to date has begun strongly across all products and regions. In the Hospital product group, contributions include ongoing change in clinical practice, and a good response to new product introductions.

In addition, early indications are that the year to date includes a relatively high hospital census during the period in both the Northern and Southern Hemispheres as Northern Hemisphere seasonal hospitalisations persisted into the beginning of this current financial year and hospitals have returned to more normalised staffing and capacity.

This has seen investors gobbling up the ASX healthcare share en masse today, likely positioning for this expected growth.

Positive updates for the full year, too

Fisher & Paykel has also revised its full-year guidance. The ASX healthcare share didn't change its revenue expectations – it still expects sales of $1.9 billion to $2.0 billion.

However, it raised its profit forecasts by around $10 million, now estimating the bottom line at between $320 million and $370 million.

The company expects to maintain its current business momentum, supported by continued changes in clinical practice and the success of new products. CEO Gradon expressed optimism about the year ahead:

We expect the remainder of the financial year for our Hospital product group to have similar underlying contributions from changes to clinical practice and new product introductions.

We have not changed our view on the revenue guidance range for the full year due to the additional and variable impact of Northern Hemisphere seasonal hospitalisation rates, which historically occur towards the end of our second half.

Gradon described Fisher & Paykel's hospital products as "market leaders", and said that its sleep apnea masks were getting positive reviews.

Wilson's rated the stock a buy earlier this month, while Equity Trustees has placed the ASX healthcare stock on its 'shopping list' of top-quality businesses to consider for the long term.

ASX healthcare share snapshot

Fisher & Paykel's share price has been on a tear this year. The ASX healthcare share has just updated its outlook for both the first half and full year for FY25.

Shares in the company have climbed 54% in the last 12 months and are up 46.6% year to date.

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

3 ASX companies that are global leaders

Numerous ASX companies have extended their reach beyond Australia to dominate in their fields.

Read more »

Three people in a corporate office pour over a tablet, ready to invest.
Broker Notes

Bell Potter just slapped a buy on this ASX 200 share offering a 30% return

Which stock is being tipped as a buy? Let's find out.

Read more »

Happy healthcare workers in a labs
Healthcare Shares

Macquarie initiates coverage of Neuren Pharmaceuticals shares; forecasts 45% upside

The broker described Neuren as a standout in the ASX biotech sector.

Read more »

A woman leans forward with her hand behind her ear, as if trying to hear information.
Healthcare Shares

Does Macquarie think Cochlear shares are a buy, hold, or sell?

Macquarie has released a new note on Cochlear following the company's FY25 profit guidance change.

Read more »

Stethoscope with a piggy bank in the middle.
Healthcare Shares

Up 18% this year, does Macquarie expect NIB shares to go higher?

This expert has a bold prediction for NIB.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why is the Mesoblast share price up 11% in June?

The ASX biotech share reached a 10-week high of $1.94 today.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Up 51% since the tariff pain, is it too late to buy Pro Medicus shares?

After rocketing higher, is the ASX healthcare share still an opportunity?

Read more »

A woman wearing a yellow shirt smiles as she checks her phone.
Healthcare Shares

CSL shares push higher on US FDA approval

This biotech giant has been given a boost in the United States.

Read more »